News | Clinical Decision Support | October 13, 2016

Artificial Intelligence Expedites Breast Cancer Risk Prediction

Machine learning algorithm correlates mammograms, patient chart data to assess individual patient risk, saving over 500 physician hours

breast cancer risk, machine learning algorithm, Houston Methodist, mammograms

October 13, 2016 — Researchers at Houston Methodist have developed an artificial intelligence (AI) software that reliably interprets mammograms, assisting doctors with a quick and accurate prediction of breast cancer risk. According to a new study published online Aug. 29 in Cancer, the computer software intuitively translates patient charts into diagnostic information at 30 times human speed and with 99 percent accuracy.

"This software intelligently reviews millions of records in a short amount of time, enabling us to determine breast cancer risk more efficiently using a patient's mammogram. This has the potential to decrease unnecessary biopsies," said Stephen T. Wong, Ph.D., P.E., chair of the Department of Systems Medicine and Bioengineering at Houston Methodist Research Institute.

The team led by Wong and Jenny C. Chang, M.D., director of the Houston Methodist Cancer Center used the AI software to evaluate mammograms and pathology reports of 500 breast cancer patients. The software scanned patient charts, collected diagnostic features and correlated mammogram findings with breast cancer subtype. Clinicians used results, like the expression of tumor proteins, to accurately predict each patient's probability of breast cancer diagnosis.

Currently, when mammograms fall into the suspicious category, a broad range of 3 to 95 percent cancer risk, patients are recommended for biopsies. Over 1.6 million breast biopsies are performed annually nationwide, and about 20 percent are unnecessarily performed due to false-positive mammogram results of cancer free breasts, estimates the ACS. The Houston Methodist team hopes this artificial intelligence software will help physicians better define the percent risk requiring a biopsy, equipping doctors with a tool to decrease unnecessary breast biopsies.

Manual review of 50 charts took two clinicians 50-70 hours. AI reviewed 500 charts in a few hours, saving over 500 physician hours.

"Accurate review of this many charts would be practically impossible without AI," said Wong.

Co-authors of the study included Tajel Patel, M.D., Mamta Puppala, Richard Ogunti, M.D., Joe. E. Ensor, Ph.D., Tian Cheng He, Ph.D., and Angel A. Rodriguez, M.D. (Houston Methodist); Jitesh B. Shewale, Ph.D. (University of Texas School of Public Health); and Donna P. Ankerst, Ph.D. (University of Texas Health Science Center at San Antonio and Technical University of Munich, Germany).

The research was supported in part by the John S. Dunn Research Foundation.

For more information: www.canceronline.wiley.com

Related Content

Hologic Opens Learning and Experience Centre in Zaventem, Belgium
News | Women's Health | March 21, 2019
Hologic Inc. opened its first Learning and Experience Centre in Zaventem, Belgium. The state-of-the-art facility...
QTbreasthealth Opens Breast Imaging Center in San Jose
News | Ultrasound Women's Health | March 20, 2019
QTbreasthealth has opened a new center in San Jose, Calif. The new location is now open and booking appointments for...
Older Biologic Age Linked to Elevated Breast Cancer Risk
News | Women's Health | March 19, 2019
Biologic age, a DNA-based estimate of a person’s age, is associated with future development of breast cancer, according...
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...
Fujifilm Launches Three New Software Tools for Aspire Cristalle Digital Mammography System
Technology | Mammography | March 15, 2019
Fujifilm Medical Systems USA announced it has fulfilled all U.S. Food and Drug Administration (FDA) regulatory...
Hologic Receives CE Mark for Three-in-One Omni Hysteroscope
News | Endoscopes | March 14, 2019
Hologic Inc. announced it has received a CE mark in Europe for its Omni hysteroscope, a three-in-one modular scope with...
CT, Mammograms Offer Clues to Preventing Heart Problems After Cancer Treatment
News | Cardio-oncology | March 13, 2019
An imaging procedure commonly performed before starting cancer treatment can provide valuable clues about a patient's...
Sponsored Content | Videos | Artificial Intelligence | March 13, 2019
At RSNA 2018, iCad showed how its...
Lucence Diagnostics to Develop AI Tools for Liver Cancer Treatment

Pseudocolor accentuated CT scan image of a liver tumor. Image courtesy of Lucence Diagnostics.

News | Oncology Diagnostics | March 12, 2019
Genomic medicine company Lucence Diagnostics announced a new project to develop artificial intelligence (AI) algorithms...
Hologic Earns CE Mark for LOCalizer Wireless Breast Lesion Localization System
News | Breast Imaging | March 07, 2019
Hologic Inc. announced the granting of a CE Mark to the LOCalizer wireless radio frequency identification (RFID) breast...